Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

Determinants of adherence in a cohort of Belgian HIV patients: a pilot study.

Degroote S, Vogelaers D, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, Pelgrom J, Van Wanzeele F, Verhofstede C, Vancauwenberghe J, Vandijck D.

Acta Clin Belg. 2014 Apr;69(2):111-5. doi: 10.1179/0001551214Z.00000000035.

PMID:
24724750
2.

Socio-economic, behavioural, (neuro)psychological and clinical determinants of HRQoL in people living with HIV in Belgium: a pilot study.

Degroote S, Vogelaers DP, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, Pelgrom J, Van Wanzeele F, Verhofstede C, Vandijck DM.

J Int AIDS Soc. 2013 Dec 12;16:18643. doi: 10.7448/IAS.16.1.18643.

3.

Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections.

Chalmet K, Staelens D, Blot S, Dinakis S, Pelgrom J, Plum J, Vogelaers D, Vandekerckhove L, Verhofstede C.

BMC Infect Dis. 2010 Sep 7;10:262. doi: 10.1186/1471-2334-10-262.

4.

Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.

Malan N, Su J, Mancini M, Yang R, Wirtz V, Absalon J, McGrath D; CASTLE Study Team.

AIDS Care. 2010 Jun;22(6):677-86. doi: 10.1080/09540120903334641.

PMID:
20467943
6.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team.

Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.

PMID:
18722869
7.

Impact of Delta 32-CCR5 heterozygosity on HIV-1 genetic evolution and variability--a study of 4 individuals infected with closely related HIV-1 strains.

Chalmet K, Van Wanzeele F, Demecheleer E, Dauwe K, Pelgrom J, Van Der Gucht B, Vogelaers D, Plum J, Stuyver L, Vandekerckhove L, Verhofstede C.

Virology. 2008 Sep 30;379(2):213-22. doi: 10.1016/j.virol.2008.06.036. Epub 2008 Aug 9.

8.

Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.

Verhofstede C, Van Wanzeele F, Van Der Gucht B, Pelgrom J, Vandekerckhove L, Plum J, Vogelaers D.

J Med Virol. 2007 Sep;79(9):1254-60.

PMID:
17607772
9.

Families affected by HIV: parents' and children's characteristics and disclosure to the children.

Nöstlinger C, Jonckheer T, de Belder E, van Wijngaerden E, Wylock C, Pelgrom J, Colebunders R.

AIDS Care. 2004 Jul;16(5):641-8.

PMID:
15223533
10.

Neuropsychiatric reaction induced by abacavir.

Colebunders R, Hilbrands R, De Roo A, Pelgrom J.

Am J Med. 2002 Nov;113(7):616. No abstract available.

PMID:
12459415
11.

Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).

Florence E, Dreezen C, Desmet P, Smets E, Fransen K, Vandercam B, Pelgrom J, Clumeck N, Colebunder R.

Antivir Ther. 2001 Dec;6(4):255-62.

PMID:
11878407
12.

Burkitt's lymphoma shortly after an acute HIV infection, treated with highly active retroviral treatment.

Colebunders R, Dohmen S, Van de Velde A, Pelgrom J, Hermans P.

Acta Clin Belg. 2001 Sep-Oct;56(5):321-2. No abstract available.

PMID:
11770227
13.

The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.

Gisolf EH, Jurriaans S, Pelgrom J, van Wanzeele F, van der Ende ME, Brinkman K, Borst MJ, de Wolf F, Japour AJ, Danner SA.

AIDS. 2000 Mar 10;14(4):405-13.

PMID:
10770543
14.

The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe.

Moyle G, Pozniak A, Opravil M, Clumeck N, DelFraissy JF, Johnson M, Pelgrom J, Reynes J, Vittecoq D, DeLora P, Salgo M, Duff F.

J Acquir Immune Defic Syndr. 2000 Feb 1;23(2):128-37.

PMID:
10737427
15.

Cutaneous ulcer caused by Mycobacterium avium and recurrent genital herpes after highly active antiretroviral therapy.

Pelgrom J, Bastian I, Van den Enden E, Portaels F, Colebunders R.

Arch Dermatol. 2000 Jan;136(1):129. No abstract available.

PMID:
10632226
16.

Euthanasia and physician-assisted suicide.

Fleerackers Y, Colebunders R, Fonck K, Depraetere K, Pelgrom J.

Lancet. 1996 Apr 13;347(9007):1046. No abstract available.

PMID:
8606587
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk